Net sales of $139.2 million, line with the same quarter in the previous fiscal.
Continue to experience price pressures particularly in the U.S. generic business.
Gross profit of $64 million, 46% of net sales compared to $76.0 million, 54.7% of net sales.
Research and development expenses at $12.9 million compared to $1.3 million.
Selling, marketing, general and administrative expenses (SG&A) of $49.9 million increased to $25.0 million.
Operating income of $1.3 million compared to operating income of $37.0 million. The current year quarter operating result is primarily attributable to the aforementioned price erosion, as well as the on-going impact associated with our recent acquisition.